Sectors
LCTX
Lineage Cell Therapeutics, Inc.
1.10
4300 x 1.11
10700 x 1.12
bid
ask
-
0.01
0.90%
7500 @ 07:15 PM
1.10 +0.00 (0.00%)
| Ytd | -34.13% | |
| 1y | -5.98% |
1.10
day range
1.13
1.00
52 week range
2.09
| Open | 1.11 | Prev Close | 1.11 | Low | 1.10 | High | 1.13 | Mkt Cap | 278.20M |
| Vol | 580.04K | Avg Vol | 1.35M | EPS | -0.19 | P/E | N/A | Forward P/E | -3.66 |
| Beta | 1.28 | Short Ratio | 35.21 | Inst. Own | 50.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 1.16 | 200-d Avg | 1.48 | 1yr Est | 4.83 |
| Income Statement | |||
| Total Revenue | 1.07M | ||
| Revenues (USD) | 1.07M | ||
| Gross Profit | 1.07M | ||
| Operating Expenses | 9.99M | ||
| Research and Development Expense | 4.77M | ||
| Selling, General and Administrative Expense | 5.22M | ||
| Operating Income | -8.92M | ||
| Net Income | 1.48M | ||
| Net Income Common Stock | 1.48M | ||
| Net Income Common Stock (USD) | 1.48M | ||
| Consolidated Income | 1.54M | ||
| Net Income to Non-Controlling Interests | 62.00K | ||
| Earnings per Basic Share | 0.01 | ||
| Earnings per Basic Share (USD) | 0.01 | ||
| Earnings per Diluted Share | -0.03 | ||
| Earning Before Interest & Taxes (EBIT) | 1.48M | ||
| Earning Before Interest & Taxes (USD) | 1.48M | ||
| Weighted Average Shares | 249.50M | ||
| Weighted Average Shares Diluted | 261.47M | ||
| Balance Sheet | |||
| Cash and Equivalents | 37.35M | ||
| Cash and Equivalents (USD) | 37.35M | ||
| Investments | 13.47M | ||
| Investments Current | 13.47M | ||
| Trade and Non-Trade Receivables | 790.00K | ||
| Current Assets | 52.97M | ||
| Property, Plant & Equipment Net | 4.48M | ||
| Total Assets | 106.22M | ||
| Debt Current | 951.00K | ||
| Total Debt | 2.30M | ||
| Current Liabilities | 8.02M | ||
| Debt Non-Current | 1.35M | ||
| Total Liabilities | 46.42M | ||
| Accumulated Retained Earnings (Deficit) | -470.33M | ||
| Accumulated Other Comprehensive Income | -4.47M | ||
| Shareholders Equity | 60.92M | ||
| Shareholders Equity (USD) | 60.92M | ||
| Assets Non-Current | 53.25M | ||
| Total Debt (USD) | 2.30M | ||
| Deferred Revenue | 14.02M | ||
| Goodwill and Intangible Assets | 42.37M | ||
| Liabilities Non-Current | 38.41M | ||
| Trade and Non-Trade Payables | 5.39M | ||
| Tax Assets | 5.80M | ||
| Tax Liabilities | 22.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 187.00K | ||
| Net Cash Flow from Financing | 4.47M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 1.44M | ||
| Capital Expenditure | -108.00K | ||
| Issuance (Purchase) of Equity Shares | 4.47M | ||
| Issuance (Repayment) of Debt Securities | -9.00K | ||
| Net Cash Flow from Investing | 3.96M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 4.07M | ||
| Net Cash Flow from Operations | -7.24M | ||
| Effect of Exchange Rate Changes on Cash | 259.00K | ||
| Share Based Compensation | 1.60M | ||